tiprankstipranks
Quantum Biopharma Ltd. Subordinate Voting Shares Class B (QNTM)
:QNTM
Holding QNTM?
Track your performance easily

Quantum Biopharma (QNTM) Stock Price & Analysis

465 Followers

QNTM Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

42.69%1.96%50.87%
42.69% Insiders
1.96% Other Institutional Investors
50.87% Public Companies and Individual Investors

QNTM FAQ

What was Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price range in the past 12 months?
Quantum Biopharma Ltd. Subordinate Voting Shares Class B lowest stock price was $2.70 and its highest was $70.85 in the past 12 months.
    What is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s market cap?
    Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s market cap is $6.31M.
      When is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s upcoming earnings report date?
      Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s upcoming earnings report date is Mar 27, 2025 which is in 68 days.
        How were Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s earnings last quarter?
        Quantum Biopharma Ltd. Subordinate Voting Shares Class B released its earnings results on Nov 11, 2024. The company reported -$2.707 earnings per share for the quarter, missing the consensus estimate of -$2.606 by -$0.102.
          Is Quantum Biopharma Ltd. Subordinate Voting Shares Class B overvalued?
          According to Wall Street analysts Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Quantum Biopharma Ltd. Subordinate Voting Shares Class B pay dividends?
            Quantum Biopharma Ltd. Subordinate Voting Shares Class B pays a Notavailable dividend of $0.408 which represents an annual dividend yield of N/A. See more information on Quantum Biopharma Ltd. Subordinate Voting Shares Class B dividends here
              What is Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s EPS estimate?
              Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s EPS estimate is -0.77.
                How many shares outstanding does Quantum Biopharma Ltd. Subordinate Voting Shares Class B have?
                Quantum Biopharma Ltd. Subordinate Voting Shares Class B has 1,919,400 shares outstanding.
                  What happened to Quantum Biopharma Ltd. Subordinate Voting Shares Class B’s price movement after its last earnings report?
                  Quantum Biopharma Ltd. Subordinate Voting Shares Class B reported an EPS of -$2.707 in its last earnings report, missing expectations of -$2.606. Following the earnings report the stock price went down -7.919%.
                    Which hedge fund is a major shareholder of Quantum Biopharma Ltd. Subordinate Voting Shares Class B?
                    Currently, no hedge funds are holding shares in QNTM
                    ---

                    Company Description

                    Quantum Biopharma Ltd. Subordinate Voting Shares Class B

                    FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.
                    ---

                    QNTM Stock 12 Month Forecast

                    Average Price Target

                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.4,22.52307692307692,20.646153846153844,18.769230769230766,16.89230769230769,15.015384615384614,13.138461538461538,11.26153846153846,9.384615384615383,7.507692307692306,5.6307692307692285,3.753846153846151,1.8769230769230774,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":74.36,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":85.35,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":82.77,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":75,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":70.48,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":68.25,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":58.5,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":58.51,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":44.95,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.4,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    BioMarin Pharmaceutical
                    Vertex Pharmaceuticals
                    Alnylam Pharma
                    Bluebird Bio
                    Intellia Therapeutics
                    Crispr Therapeutics AG

                    Best Analysts Covering QNTM

                    1 Year
                    BJ Cook, CFASingular
                    1 Year Success Rate
                    0/1 ratings generated profit
                    0%
                    1 Year Average Return
                    -85.70%
                    reiterated a buy rating 9 months ago
                    Copying BJ Cook, CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -85.70% per trade.
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis